Amended Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

Energy Today (NRGT)

No.1 Electromechanical Industrial Park, Shandong Daiyue Economic Development Zone, Tai 'an ,China

SEC File # 333-74638 SEC CIK Code 0001499618

Annual Report For the Period Ending: March 31, 2022 (the "Reporting Period")

As of Current Report of March 31, 2022, the number of shares outstanding of our Common Stock was: 58,974,238 shares issued and restricted and 14,214 non-restricted

As of Prior Reporting ended December 31, 2021, the number of shares outstanding of our Common Stock was: 32,719,235 shares issued and restricted and 14,214 non-restricted

As of Most Recent Completed Fiscal Year Ended December 31, 2021, the number of shares outstanding of our Common Stock was: 32,719,235 shares issued and restricted and 14,214 non-restricted

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: □ No: ⊠

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: □ No: ⊠

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: □ No: ⊠ 1) Name and address(es) of the issuer and its predecessors (if any)

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

¹ "Change in Control" shall mean any events resulting in:

⁽i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

⁽ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

⁽iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Energy Today

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

<u>Texas</u>

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

<u>None</u>

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address(es) of the issuer's principal executive office:

No.1 Electromechanical Industrial Park, Shandong Daiyue Economic Development Zone, Tai 'an ,China

The address(es) of the issuer's principal place of business: Check box if principal executive office and principal place of business are the same address:

No.1 Electromechanical Industrial Park, Shandong Daiyue Economic Development Zone, Tai 'an ,China

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: □ No: ⊠

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

<u>NONE</u>

2) Security Information

Trading symbol:	NRGT
Exact title and class of securities outstanding:	Common
CUSIP:	SEC File # 333-74638
Par or stated value:	<u>0.001</u>
Total shares authorized:	250,000,000 as of date: March 31, 2022
Total shares outstanding:	58,974,238 as of date: March 31, 2022

Number of shares in the Public Float ² :	<u>14,214</u>	as of date:	March 31, 2022
Total number of shareholders of record:	27	as of date:	March 31, 2022

All additional class(es) of publicly traded securities (if any):

Trading symbol:	NONE
Exact title and class of securities outstanding: CUSIP:	
Par or stated value: Total shares authorized: Total shares outstanding:	as of date: as of date:

Transfer Agent

Name:	<u>Clear Trust LLC</u>
Phone:	<u>813-235-4490</u>
Email:	info@cleartrustonline.com
Address:	16540 Pointe Village Dr. Suite 205 Lutz, Florida 33558

Is the Transfer Agent registered under the Exchange Act?³ Yes: \square No: \square

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: \boxtimes

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u>				*Right	t-click the row	vs below and select	"Insert" to add rows	as needed.	
Date Common: Preferred:									
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per	Were the shares issued at a discount to market price at the time	Individual/ Entity Shares were issued to (entities must have individual with voting / investment	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of	Restricted or Unrestricted as of this filing.	Exemption or Registratic Type.

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

	returned to		share) at	of	control	Services	
	treasury)		Issuance	issuance?	disclosed).	Provided	
				(Yes/No)			
Shares Outstanding	n on Date of This	s Report:	I	I			
		e rieperti					
	Ending	Balance					
Ending Balance:							
Date	Common	1:					
	Preferred	:					

Example: A company with a fiscal year end of December 31st, in addressing this item for its quarter ended September 30, 2020, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2018 through September 30, 2020 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements:

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)

Use the space below to provide any additional details, including footnotes to the table above:

4) Financial Statements

A. The following financial statements were prepared in accordance with:

⊠ U.S. GAAP □ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name:	Chai,fengchen;
Title:	<u>CEO</u>
Relationship to Issuer:	<u>CEO</u>

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

C. Balance sheet;

Energy Today, Inc.	
(Formerly Yellow7, Inc	c.)
Condensed Balance She	eets
31-Mar-22	
ASSETS	
Current Assets:	
Cash and cash equivalents	\$0.00
Accounts receivable, net of allowance of \$3,500 and \$15,00	\$0.00
Employee advances	\$0.00
Deferred tax asset	-
Total current assets	\$0.00
Furniture and Equipment, net	\$0.00
Other Assets:	
Intangibles	\$5,897,424
Deferred tax asset - non-current	-
Total other assets	\$5,897,424
Total Assets	\$5,897,424
LIABILITIES AND STOCKHOLDERS' EQUITY	
Liabilities:	
Accounts payable and accrued expenses	\$7,718.00
Loans payable - stockholders	\$0.00
Loans payable - current portion	\$0.00
Total current liabilities	\$0.00
	\$0.00
Non-current Liabilities	
Loans payable - net of current portion	\$ -
Total non-current liabilities	
Stockholders' Equity (Deficit):	
Common stock, \$0.0001 par value; 250,000,000 shares aut	horized,
58,974,238 shares issued and outstanding, respectively	\$ 5,897,423.80
Additional paid in capital	
Treasury stock, at cost	
Retained Earnings (Deficit)	(\$7,718)
Total Stockholder's Equity and Liabilities	\$ 5,897,424

D. Statement of income;

ations
31, 2022
\$0
\$0
\$0
\$0
\$0
\$0
\$638
\$4,800
\$480
\$1,800
\$7,718
\$7,718
(\$7,718)

E. Statement of cash flows;

Energy Today, Inc.	
(Formerly Yellow7, Inc.)	
Condensed Statements of Cash Fl	
For the Three Months Ended March 3	1, 2022
(Unaudited)	
Cash flows from operating activities:	
Net loss	(\$7.710)
Adjustments to reconcile net loss to net cash	(\$7,718)
by operating activities:	
Depreciation expense Accounts receivable	
Prepaid expenses	
Deferred tax asset - current	
Accounts payable and accrued expenses	
Net cash provided (used) by operating activities	(\$7,718)
Net cash provided (used) by operating activities	(\$7,710)
Cash flows from financing activities:	
Shareholders' loans	
Loans payable	
Net cash used by financing activities	
Net increase in cash	
Cash at beginning of period	\$ -
Cash at end of period	\$ -
Supplemental cash flow information:	
Cash paid during the period for:	
Interest	
Income taxes	
Noncash Transactions	
Purchase of intangible asset for common stock	

F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)

				Energy Today, In	с.				
				(Formerly Yellow7,	Inc.)				
			Statemer	nt of Stockholders' E	quity (Deficit)				
				31-Mar-22					
				(Unaudited)					
								Retained	Total Stockholders'
					Additional Paid in Capital			Earnings	
	Common \$	Stock	Preferr	ed Class A		Treasu	Treasury Stock		Deficiency
	Shares	Amount	Shares	Amount		Shares	Amount		
Balance - January 1, 2022	32,719,235	\$0.10		\$	- \$-	-	\$	- \$0	\$3,271,923.50
Purchase of Stock	1,255,003	\$0.10	25,000,000	\$0.10					\$2,625,500.30
Cancellation of treasury stock	-	-			-	-			-
Net loss	-	-			-	-		(\$7,718)	-\$7,718.00
Balance - March 31, 2022	58,974,238	0.1				-		\$ (7,718.00)	\$5,889,705.80
Issuance of common stock to acquire	26,255,003								
	-					-			
Net loss	-	-	-			-		-	
Balance - March 31, 2022	58,974,238	\$0.100		\$	- \$-	-	\$	(\$7,718)	\$5,889,705.80

G. Financial notes; and 1.0 NOTE 1-OVERVIEW

1.1 Liquidity

The accompanying unaudited consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The company change management as of July 7, 2016, after the death of the old CEO Tom Makmann. The new CEO Kate Bahnsen sold the furniture and collected the account receivable making a sum of \$174,617 to pay the liabilities \$227,002 reducing the liability to only \$52,835. That liability was settled to \$0 in 2018.

In March 31, 2022 the CEO cancel all the debt owed to management for salaries not paid and payment to transfer agent for a total of \$199,051 plus the loss of 221 of the company for a total of \$23,153. The company has only a debt to the transfer agent for a total of \$28,880 that was paid of the first quarter of 2022.

Any of the following factors could result in insufficient capital to fund the Company's operations for a period significantly shorter than twelve months:

- if the Company's capital requirements or cash flow vary materially from its current projections.
- if the Company is unable to timely raise capital for the requirements of its joint venture agreements and to cover its operating expenses; or
- if other unforeseen circumstances occur.

The Company's inability to fund its operations may require the Company to substantially curtail its business activities. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. The Company's plans for correcting these deficiencies include ongoing efforts to raise new capital and negotiating suitable repayment terms for outstanding obligations. The unaudited consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the inability of the Company to continue as a going concern.

1.2 NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

1.2.1 Basis of Presentation

The accompanying unaudited consolidated financial statements of Energy Today (NRGT) have been prepared in conformity with accounting principles regarding interim financial reporting. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for annual financial statements and should be read in conjunction with the unaudited consolidated financial statements previously reported by the Company. In the opinion of management, the accompanying unaudited financial statements contain most all adjustments, consisting only of adjustments of a normal recurring nature, necessary for a fair presentation of the Company's financial position as of December 31, 2018, and its results of operations for the periods presented. These unaudited consolidated financial statements are not necessarily indicative of results to be expected for future periods. The company is currently register in Texas. The company has merger with Shandong Jusheng Biotechnology Co., Ltd. was established in 2016. The company belongs to the biotechnology industry, which is in line with the development direction of the national health industry plan and is a strategic emerging industry encouraged by the state. Mainly engaged in weight management, oral beauty, oral health, gastrointestinal regulation, sleep improvement, nutrition and health care, health and nourishment, beauty and skin care, and eight series of sub-categories! In recent years, the company has pioneered, innovated, and paid close attention to the key elements of enterprise development, and achieved good operating results. The production and sales of main products have increased significantly.

Shandong Jusheng Biology attaches great importance to scientific development and has won honors such as China's Green Health Food, China's High-tech Products, Social New Retail Credit Demonstration and Certification Enterprise, and China's Great Health Industry Demonstration Unit. The company continues to promote technological progress and has several invention patents, and more than 10 new patents.

In 2016, Shandong Jusheng Biological Peony Seed Oil Compound Peptide was launched. The product was independently developed by Shandong Jusheng Biological, and added small molecular peptides. It has a small molecular weight, high purity, good water solubility, and is more easily absorbed by the human body. Since the product was launched, it has been deeply recognized and praised by consumers because of its small molecule, easy-to-absorb technology, and health concept. In recent years, the company has successively developed and launched diversified products such as peony collagen peptide,

peony oligopeptide powder, and peony seed oil peptide microcapsule powder, which are well received by consumers.

In the future, in addition to actively expanding an existing business, the company will also seize the opportunity of the strategic development of "Healthy China", increase product research and development efforts, and seize the big health market with high-quality products and value-added services.

Shandong Jusheng Biotechnology Co., Ltd. will continue to practice the corporate mission of "continuous innovation, the pursuit of health", with the help of technological innovation and the strong driving force of the market, to build a modern biotechnology enterprise with steady development and continuous growth, and make contributions to the country's biological industry. They make new efforts to make positive contributions to the pursuit of health and beauty!

1.2.2 Critical Accounting Policies and Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates and assumptions. Certain amounts from prior periods have been reclassified to conform with current period presentation.

1.2.3 Cash and Cash Equivalents

The Company considers all cash and investments with original maturities of three months or less to be cash equivalents.

1.2.4 Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. Expenditures for minor replacements, maintenance and repairs which do not increase the useful lives of the property and equipment are charged to operations as incurred. Major additions and improvements are capitalized. Depreciation and amortization are computed using the straight-line method over estimated useful lives of 5 years.

1.2.5 Intangible Assets

In accordance with ASC subtopic 350-10, Intangibles, Goodwill and Others, the goodwill impairment analysis compares the fair value of each reporting unit to its carrying value, including goodwill. The Company evaluates the remaining useful life of an intangible asset that is being amortized each reporting period to determine whether events and circumstances warrant a revision to the remaining period of amortization, and as such all Goodwill was written off in this accounting period.

1.2.6 Accounting for the Impairment of Long-Lived Assets

No Long-lived assets.

1.2.7 Advertising

The Company charges advertising costs to expense as incurred. There were no advertising expenses for the twelve months' periods ending March 31, 2022.

1.2.8 Concentrations of Risk

Credit losses, if any, have been provided for in the financial statements and are based on management's expectations. The Company does not believe that it is subject to any unusual risks or significant risks in the normal course of its business.

1.2.9 Revenue Recognition

We recognize revenue in accordance with Staff Accounting Bulletin ("SAB") No. 104, Revenue Recognition, Corrected Copy. Under SAB No. 104, revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the seller's price to the buyer is fixed or determinable, and collectability is reasonably assured. Revenue is recognized net of sales tax. We apply the specific provisions of SFAS No. 48, Revenue Recognition when Right of Return Exists. Under SFAS No. 48, product revenue is recorded at the transfer of title to the products to a customer, net of estimated allowances and returns and sales incentives. Transfer of title occurs and risk of ownership passes to a customer at the time of acceptance by the customer, depending on the terms of our agreement with a particular customer. For transactions not satisfying the conditions for revenue recognition under SFAS No. 48, product revenue is deferred until the conditions are met, net of an estimate for cost of sales.

1.2.10 Income Taxes

The Company accounts for income taxes under ASC topic 740, Income Taxes, ASC topic 740 defines an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. ASC topic 740 further requires that a tax position must be more likely than not to be sustained before being recognized in the financial statements, as well as the accrual of interest and penalties as applicable on unrecognized tax positions. Deferred income taxes are recognized for the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at each period end, based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The provision for income taxes represents the tax payable for the period, if any, and the change during the period in deferred tax assets and liabilities.

1.2.11 Litigation and Other Contingencies

The Company discloses material contingencies deemed to be reasonably possible and accrues loss contingencies when, in consultation with legal advisors, the Company concludes that a loss is probable and reasonably estimable. The ability to predict the ultimate outcome of such matters involves

judgments, estimates and inherent uncertainties. The actual outcome of such matters could differ materially from management's estimates.

1.2.11 Computation of Net Loss (Loss) Per Common Share.

The Company calculates income/loss per share in accordance with FASB ASC topic 260, Earnings Per Share. Basic income/loss per share is computed by dividing the net income/loss available to common shareholders by the weighted-average number of common shares outstanding. Diluted income/loss per share is computed similar to basic loss per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.

2 NOTE 2 – FAIR VALUE MEASUREMENTS

The Company's financial assets that are measured on a recurring basis at fair value.

2.1 Level 1.

The Company utilizes the market approach to determine the fair value of its assets and liabilities under Level 1 of the fair value hierarchy. The market approach pertains to transactions in active markets involving identical or comparable assets or liabilities.

2.2 Level 2.

The fair values determined through Level 2 of the fair value hierarchy are derived principally from or corroborated by observable market data. Inputs include quoted prices for similar assets, liabilities (risk adjusted), and market-corroborated inputs, such as market comparable, interest rates, yield curves, and other items that allow value to be determined.

2.3 Level 3.

The fair values determined through Level 3 of the fair value hierarchy are derived principally from unobservable inputs to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset (or similar assets) at the measurement date. As of December 31, 2020, no fair value measurements for assets or liabilities under Level 3 were recognized in the Company's consolidated financial statements. There were no changes in the Company's valuation techniques during the twelve months ending December 31, 2020. The Company is not exposed to changes in interest rates which could result in cash flow risks.

	31-March 21	31-March-22	
Vehicles	\$ -	\$ -	
Equipment	\$-	\$-	
Furniture and Fixtures	\$-	\$-	
Accumulated Depreciation	\$-	\$-	

3. NOTE 3- FURNITURE AND EQUIPMENT

The above reflects US operations. Colombian Furniture and Equipment will be stated in future filings.

4. NOTE 4 – INTANGIBLE ASSETS

Yellow7, Inc. (the "Company" or "Yellow7") is an operating company. The Company was organized as a limited liability company on February 26, 2007 under the laws of the state of Texas. On July 13, 2010, the Company converted to a corporation in the same jurisdiction.

We initially began operations in 1998 as a creative advertising outlet by assisting Dallas-area advertising agencies to develop and execute online marketing strategies. Yellow7 developed its own brand and customer base while maintaining key relationships with several local, regional and national public relations and advertising firms. In 2006, we re-branded as Yellow7 interactive and operated as a full service interactive marketing agency. Previously outsourced services were now being handled in-house which was more efficient and less costly.

As the web has developed, so too has our business model. What began as a creative-only firm has expanded into nearly all aspects of online marketing and advertising. Our client services include website design, development, maintenance services, search engine optimization (seo / sem), paid search marketing (ppc), social media advertising, branding, email marketing, banner/rich media advertising, media planning/buying, video, web application development, mobile design/development, mobile application development, ecommerce and other related services. We intend to continue developing real solutions for our clients while focusing primarily on online advertising methods. Our primary objective is to grow our core competencies while expanding into new industry related opportunities.

The principal executive offices was located at 104 Hardwicke Lane, Little Elm, TX 75068 and our telephone number is (972) 731-6720.

5 NOTE 5— Employment Contract

The Company has 100 employees in China

5.1 Employee Retirement Plan

The Company has no retirement plans for its current employees

5.2 Financial Agreements

The Company has no outstanding financial agreements as of December 31, 2018.

H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

Attach

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Shandong Jusheng Biotechnology Co., Ltd. was established in 2016. The company belongs to the biotechnology industry, which is in line with the development direction of the national health industry plan and is a strategic emerging industry encouraged by the state. Mainly engaged in weight management, oral beauty, oral health, gastrointestinal regulation, sleep improvement, nutrition and health care, health and nourishment, beauty and skin care, and eight series of sub-categories! In recent years, the company has pioneered, innovated, and paid close attention to the key elements of enterprise development, and achieved good operating results. The production and sales of main products have increased significantly.

Shandong Jusheng Biology attaches great importance to scientific development and has won honors such as China's Green Health Food, China's High-tech Products, Social New Retail Credit Demonstration and Certification Enterprise, and China's Great Health Industry Demonstration Unit. The company continues to promote technological progress and has several invention patents, and more than 10 new patents.

In 2016, Shandong Jusheng Biological Peony Seed Oil Compound Peptide was launched. The product was independently developed by Shandong Jusheng Biological, and added small molecular peptides. It has a small molecular weight, high purity, good water solubility, and is more easily absorbed by the human body. Since the product was launched, it has been deeply recognized and praised by consumers because of its small molecule, easy-to-absorb technology, and health concept. In recent years, the company has successively developed and launched diversified products such as peony collagen peptide, peony oligopeptide powder, and peony seed oil peptide microcapsule powder, which are well received by consumers.

In the future, in addition to actively expanding an existing business, the company will also seize the opportunity of the strategic development of "Healthy China", increase product research and development efforts, and seize the big health market with high-quality products and value-added services.

Shandong Jusheng Biotechnology Co., Ltd. will continue to practice the corporate mission of "continuous innovation, the pursuit of health", with the help of technological innovation and the strong driving force of the market, to build a modern biotechnology enterprise with steady development and continuous growth, and make contributions to the country's biological industry. They make new efforts to make positive contributions to the pursuit of health and beauty!

B. Please list any subsidiaries, parents, or affiliated companies.

Shandong Jusheng Biotechnology Co., Ltd. was established in 2016. The company belongs to the biotechnology industry, which is in line with the development direction of the national health industry plan and is a strategic emerging industry encouraged by the state. Mainly engaged in weight management, oral beauty, oral health, gastrointestinal regulation, sleep improvement, nutrition and health care, health and nourishment, beauty and skin care, and eight series of sub-categories! In recent years, the company has pioneered, innovated, and paid close attention to the key elements of enterprise development, and achieved good operating results. The production and sales of main products have increased significantly.

Shandong Jusheng Biology attaches great importance to scientific development and has won honors such as China's Green Health Food, China's High-tech Products, Social New Retail Credit Demonstration and Certification Enterprise, and China's Great Health Industry Demonstration Unit. The company continues to promote technological progress and has several invention patents, and more than 10 new patents.

In 2016, Shandong Jusheng Biological Peony Seed Oil Compound Peptide was launched. The product was independently developed by Shandong Jusheng Biological, and added small molecular peptides. It has a small molecular weight, high purity, good water solubility, and is more easily absorbed by the human body. Since the product was launched, it has been deeply recognized and praised by consumers because of its small molecule, easy-to-absorb technology, and health concept. In recent years, the company has successively developed and launched diversified products such as peony collagen peptide, peony oligopeptide powder, and peony seed oil peptide microcapsule powder, which are well received by consumers.

In the future, in addition to actively expanding an existing business, the company will also seize the opportunity of the strategic development of "Healthy China", increase product research and development efforts, and seize the big health market with high-quality products and value-added services.

Shandong Jusheng Biotechnology Co., Ltd. will continue to practice the corporate mission of "continuous innovation, the pursuit of health", with the help of technological innovation and the strong driving force of the market, to build a modern biotechnology enterprise with steady development and continuous growth, and make contributions to the country's biological industry. They make new efforts to make positive contributions to the pursuit of health and beauty!

C. Describe the issuers' principal products or services.

Shandong Jusheng Biotechnology Co., Ltd. was established in 2016. The company belongs to the biotechnology industry, which is in line with the development direction of the national health industry plan and is a strategic emerging industry encouraged by the state. Mainly engaged in weight management, oral beauty, oral health, gastrointestinal regulation, sleep improvement, nutrition and health care, health and nourishment, beauty and skin care, and eight series of sub-categories! In recent years, the company has pioneered, innovated, and paid close attention to the key elements of enterprise development, and achieved good operating results. The production and sales of main products have increased significantly.

Shandong Jusheng Biology attaches great importance to scientific development and has won honors such as China's Green Health Food, China's High-tech Products, Social New Retail Credit Demonstration and Certification Enterprise, and China's Great Health Industry Demonstration Unit. The company continues to promote technological progress and has several invention patents, and more than 10 new patents.

In 2016, Shandong Jusheng Biological Peony Seed Oil Compound Peptide was launched. The product was independently developed by Shandong Jusheng Biological, and added small molecular peptides. It has a small molecular weight, high purity, good water solubility, and is more easily absorbed by the human body. Since the product was launched, it has been deeply recognized and praised by consumers because of its small molecule, easy-to-absorb technology, and health concept. In recent years, the company has successively developed and launched diversified products such as peony collagen peptide, peony oligopeptide powder, and peony seed oil peptide microcapsule powder, which are well received by consumers.

In the future, in addition to actively expanding an existing business, the company will also seize the opportunity of the strategic development of "Healthy China", increase product research and development efforts, and seize the big health market with high-quality products and value-added services.

Shandong Jusheng Biotechnology Co., Ltd. will continue to practice the corporate mission of "continuous innovation, the pursuit of health", with the help of technological innovation and the strong driving force of the market, to build a modern biotechnology enterprise with steady development and continuous growth, and make contributions to the country's biological industry. They make new efforts to make positive contributions to the pursuit of health and beauty!

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

No lease of any assets or own any assets.

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% of more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
Zhang,rongrong	Shandong	No.1	<u>25,000,000</u>	<u>common</u>	<u>%</u>	
	Jusheng	Electromechanical				
	Biotechnology	Industrial Park,				
	Co., Ltd	Shandong Daiyue				
		Economic				
		Development				

	Zone, Tai 'an ,China		

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

NONE

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

NONE

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding, or judgment has not been reversed, suspended, or vacated; or

NONE

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

NONE

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

No litigation has been filed or is pending on the state of New York where the company is register.

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name:	
Firm:	
Address 1:	
Address 2:	
Phone:	
Email:	

Accountant or Auditor

nbia
1

Investor Relations

Name:	
Firm:	
Address 1:	
Address 2:	
Phone:	
Email:	

Other Service Providers

Provide the name of any other service provider(s) that **that assisted**, **advised**, **prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name:	
Firm:	
Nature of Services:	
Address 1:	
Address 2:	
Phone:	
Email:	

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Katharina Nanny Bahnsen certify that:

1. I have reviewed this annual	disclosure statements	of Energy Toda	v ticker NRGT	as of March 31.	2022:
		or Enorgy roud	y 10101 141 CO 1	ao or maron or,	2022,

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

June 27, 2022

Nanny Kathanina Bahnsen

Katharina Nanny Bahnsen CEO (Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Katharina Nanny Bahnsen certify that:

1. I have reviewed this annual disclosure statements of Energy Today ticker NRGT as of March 31, 2022.

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

June 27, 2022

Nanny Kathanna Bahnsen

Katharina Nanny Bahnsen CFO (Digital Signatures should appear as "/s/ [OFFICER NAME]")